Jiangxi Rimag Group (HKG:2522) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥760.6m (down 18% from FY 2023).
- Net loss: CN¥45.9m (down by 203% from CN¥44.4m profit in FY 2023).
- CN¥0.13 loss per share (down from CN¥0.13 profit in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Jiangxi Rimag Group Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates.
Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 7.3% growth forecast for the Healthcare industry in Hong Kong.
Performance of the Hong Kong Healthcare industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Be aware that Jiangxi Rimag Group is showing 1 warning sign in our investment analysis that you should know about...
Valuation is complex, but we're here to simplify it.
Discover if Jiangxi Rimag Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.